A  Phase IV Study of the Safety and Efficacy of CinnoPar^® in Iranian Patients with Osteoporosis

Table 1

Patients’ demographic and baseline characteristics.

Variable	Result
Population	193
Age (y)	65 ± 11
Height (cm)	156 ± 8.7
Weight (kg)	64 ± 12.2
BMI	26.1 ± 4.8
Female	178 (92)
Smoking	8 (4)
Alcohol consumption	7 (4)
Tea/coffee consumption ≥1 cup per day	167 (87)
Prior osteoporosis treatment
Total	93 (48)
Calcitonin	2 (2)
Bisphosphonate	91 (98)
Medical history
Allergic diseases	15 (8)
Hepatic impairment	4 (2)
Renal impairment	10 (5)
Gastrointestinal diseases	20 (10)
Rheumatic diseases	48 (25)
Thyroid dysfunction	13 (7)
Parathyroid dysfunction	1 (1)
Osteopenia/osteoporosis diagnosis
As per T-score of the hip
Screened	160 (83)
Normal	7 (4)
Osteopenia	63 (39)
Osteoporosis	90 (56)
As per T-score of the spine
Screened	158 (82)
Normal	7 (4)
Osteopenia	23 (15)
Osteoporosis	128 (81)
Total serum calcium (mg/dL)
Baseline	9.4 ± 0.55

Data are presented as mean ± SD or n (%), where applicable. SD = standard deviation.